Salivary gland cancer in the era of immunotherapy: can we exploit tumor microenvironment?

References

• Carlson ER, Ord RA. Salivary gland pathology: diagnosis and management. New Jersey, USA: John Wiley & Sons; 2015.
   Google Scholar
• El-Naggar AK, Chan JKC, Grandis JR, et al. WHO classification of head and neck tumours. Lyon, France: International Agency for Research on Cancer; 2017.
   Google Scholar
• Ross JS, Gay LM, Wang K, et al. Comprehensive genomic profiles of metastatic and relapsed salivary gland carcinomas are associated with tumor type and reveal new routes to targeted therapies. Ann Oncol. 2017;28:2539–2546.
   PubMed Web of Science ®Google Scholar
• Schvartsman G, Pinto NA, Bell D, et al. Salivary gland tumors: molecular characterization and therapeutic advances for metastatic disease. Head Neck. 2019;41:239–247.
   PubMed Web of Science ®Google Scholar
• Tonon G, Modi S, Wu L, et al. t(11;19)(q21;p13) translocation in mucoepidermoid carcinoma creates a novel fusion product that disrupts a Notch signaling pathway [Internet]. Nat Genet. 2003;33:208–213.
   PubMed Web of Science ®Google Scholar
• Warner KA, Oklejas AE, Pearson AT, et al. UM-HACC-2A: MYB-NFIB fusion-positive human adenoid cystic carcinoma cell line. Oral Oncol. 2018;87:21–28.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network (NCCN). NCCN clinical guidelines in oncology. Head and Neck Cancers (Version 1.2020). Available from: https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf
   Google Scholar
• Chae YK, Chung SY, Davis AA, et al. Adenoid cystic carcinoma: current therapy and potential therapeutic advances based on genomic profiling [Internet]. Oncotarget. 2015;6:37117–37134.
   Google Scholar
• Mori Y, Kobayashi T, Kida Y, et al. Stereotactic radiosurgery as a salvage treatment for recurrent skull base adenoid cystic carcinoma. Stereotact Funct Neurosurg. 2005;83:202–207.
   PubMed Web of Science ®Google Scholar
• Chen AM, Garcia J, Bucci MK, et al. Recurrent salivary gland carcinomas treated by surgery with or without intraoperative radiation therapy. Head Neck. 2008;30(1):2–9.
   PubMed Web of Science ®Google Scholar
• Fushimi C, Tada Y, Takahashi H, et al. A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma. Ann Oncol. 2018;29:979–984.
   PubMed Web of Science ®Google Scholar
• Jaspers HCJ, Verbist BM, Schoffelen R, et al. Androgen receptor-positive salivary duct carcinoma: a disease entity with promising new treatment options. J Clin Oncol. 2011;29:e473–e476.
   PubMed Web of Science ®Google Scholar
• Yamamoto N, Minami S, Fujii M. Clinicopathologic study of salivary duct carcinoma and the efficacy of androgen deprivation therapy. Am J Otolaryngol. 2014;35:731–735.
   PubMed Web of Science ®Google Scholar
• Boon E, van Boxtel W, Buter J, et al. Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: a nationwide case series of 35 patients in The Netherlands. Head Neck. 2018;40:605–613.
   PubMed Web of Science ®Google Scholar
• Takahashi H, Tada Y, Saotome T, et al. Phase II trial of trastuzumab and docetaxel in patients with human epidermal growth factor receptor 2-positive salivary duct carcinoma. J Clin Oncol. 2019;37:125–134.
   PubMed Web of Science ®Google Scholar
• van Boxtel W, Boon E, Weijs WLJ, et al. Combination of docetaxel, trastuzumab and pertuzumab or treatment with trastuzumab-emtansine for metastatic salivary duct carcinoma [Internet]. Oral Oncol. 2017;198–200. DOI:10.1016/j.oraloncology.2017.06.023
   PubMed Web of Science ®Google Scholar
• Limaye SA, Posner MR, Krane JF, et al. Trastuzumab for the treatment of salivary duct carcinoma. Oncologist. 2013;18:294–300.
   PubMed Web of Science ®Google Scholar
• Li BT, Shen R, Offin M, et al. Ado-trastuzumab emtansine in patients with HER2 amplified salivary gland cancers (SGCs): results from a phase II basket trial. J Clin Orthod. 2019;37:6001.
   Google Scholar
• Jhaveri KL, Wang XV, Makker V, et al. Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q. Ann Oncol. 2019;30:1821–1830.
   PubMed Web of Science ®Google Scholar
• Perissinotti AJ, Lee Pierce M, Pace MB, et al. The role of trastuzumab in the management of salivary ductal carcinomas. Anticancer Res. 2013;33:2587–2591.
   PubMed Web of Science ®Google Scholar
• Chau NG, Hotte SJ, Chen EX, et al. A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC. Ann Oncol. 2012;23:1562–1570.
   PubMed Web of Science ®Google Scholar
• Tchekmedyian V, Sherman EJ, Dunn L, et al. Phase II study of lenvatinib in patients with progressive, recurrent or metastatic adenoid cystic carcinoma. J Clin Oncol. 2019;37:1529–1537.
   PubMed Web of Science ®Google Scholar
• Choi S, Sano D, Cheung M, et al. Vandetanib inhibits growth of adenoid cystic carcinoma in an orthotopic nude mouse model. Clin Cancer Res. 2008;14:5081–5089.
   PubMed Web of Science ®Google Scholar
• Mosconi C, de Arruda JAA, de Farias ACR, et al. Immune microenvironment and evasion mechanisms in adenoid cystic carcinomas of salivary glands. Oral Oncol. 2019;88:95–101.
   PubMed Web of Science ®Google Scholar
• Wee DTH, Thomas AA, Bradley PJ. Salivary duct carcinoma: what is already known, and can we improve survival? J Laryngol Otol. 2012;126(Suppl 2):S2–S7.
   PubMedGoogle Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–723.
   PubMed Web of Science ®Google Scholar
• Foster CC, Sher DJ, Rusthoven CG, et al. Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: a national cancer database analysis. Radiat Oncol. 2019;14:18.
   PubMed Web of Science ®Google Scholar
• Hui L, Chen Y. Tumor microenvironment: sanctuary of the devil. Cancer Lett. 2015;368:7–13.
   PubMed Web of Science ®Google Scholar
• Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer. 2016;16:582–598.
   PubMed Web of Science ®Google Scholar
• Arandkar S, Furth N, Elisha Y, et al. Altered p53 functionality in cancer-associated fibroblasts contributes to their cancer-supporting features. Proc Natl Acad Sci U S A. 2018;115:6410–6415.
   PubMed Web of Science ®Google Scholar
• Erez N, Truitt M, Olson P, et al. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner. Cancer Cell. 2010;17:135–147.
   PubMed Web of Science ®Google Scholar
• Kong J, Zhao H, Shang Q, et al. Establishment and characterization of a carcinoma-associated fibroblast cell line derived from a human salivary gland adenoid cystic carcinoma. Cell Commun Adhes. 2018;24:11–18.
   PubMed Web of Science ®Google Scholar
• Li J, Jia Z, Kong J, et al. Carcinoma-associated fibroblasts lead the invasion of salivary gland adenoid cystic carcinoma cells by creating an invasive track. PLoS One. 2016;11:e0150247.
   PubMed Web of Science ®Google Scholar
• Cordesmeyer R, Laskawi R, Schliephake H, et al. Shallow whole genome sequencing of adenoid cystic carcinomas of the salivary glands identifies specific chromosomal aberrations related to tumor progression. Oral Oncol. 2020;103:104615.
   PubMed Web of Science ®Google Scholar
• Alame M, Cornillot E, Cacheux V, et al. The molecular landscape and microenvironment of salivary duct carcinoma reveal new therapeutic opportunities. Theranostics. 2020;10(10):4383–4394. Published 2020 Mar 15.
   PubMed Web of Science ®Google Scholar
• Ferrarotto R, Mitani Y, Diao L, et al. Activating NOTCH1 mutations define a distinct subgroup of patients with adenoid cystic carcinoma who have poor prognosis, propensity to bone and liver metastasis, and potential responsiveness to notch1 inhibitors. J Clin Oncol. 2017;35:352–360.
   PubMed Web of Science ®Google Scholar
• Pathria P, Louis TL, Varner JA. Targeting Tumor-Associated Macrophages in Cancer. Trends Immunol. 2019;40:310–327.
   PubMed Web of Science ®Google Scholar
• Linxweiler M, Kuo F, Katabi N, et al. The immune microenvironment and neoantigen landscape of aggressive salivary gland carcinomas differ by subtype. Clin Cancer Res [Internet]. 2020;26:2859–2870.
   PubMed Web of Science ®Google Scholar
• Yang Z, Li H, Wang W, et al. CCL2/CCR2 axis promotes the progression of salivary adenoid cystic carcinoma via recruiting and reprogramming the tumor-associated macrophages. Front Oncol. 2019;9:231.
   PubMed Web of Science ®Google Scholar
• Shieh Y-S, Hung Y-J, Hsieh C-B, et al. Tumor-associated macrophage correlated with angiogenesis and progression of mucoepidermoid carcinoma of salivary glands. Ann Surg Oncol. 2009;16:751–760.
   PubMed Web of Science ®Google Scholar
• Riabov V, Gudima A, Wang N, et al. Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis. Front Physiol. 2014;5:75.
   PubMed Web of Science ®Google Scholar
• Raggi C, Mousa HS, Correnti M, et al. Cancer stem cells and tumor-associated macrophages: a roadmap for multitargeting strategies. Oncogene. 2016;35:671–682.
   PubMed Web of Science ®Google Scholar
• Bocci F, Gearhart-Serna L, Boareto M, et al. Toward understanding cancer stem cell heterogeneity in the tumor microenvironment. Proc Natl Acad Sci U S A. 2019;116:148–157.
   PubMed Web of Science ®Google Scholar
• Dionne LK, Driver ER, Wang XJ. Head and neck cancer stem cells: from identification to tumor immune network. J Dent Res. 2015;94:1524–1531.
   PubMed Web of Science ®Google Scholar
• Adams A, Warner K, Nör JE. Salivary gland cancer stem cells. Oral Oncol. 2013;49:845–853.
   PubMed Web of Science ®Google Scholar
• Guimarães DM, Almeida LO, Martins MD, et al. Sensitizing mucoepidermoid carcinomas to chemotherapy by targeted disruption of cancer stem cells. Oncotarget. 2016;7:42447–42460.
   PubMedGoogle Scholar
• Adams A, Warner K, Pearson AT, et al. ALDH/CD44 identifies uniquely tumorigenic cancer stem cells in salivary gland mucoepidermoid carcinomas. Oncotarget. 2015;6:26633–26650.
   PubMedGoogle Scholar
• Binnewies M, Roberts EW, Kersten K, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24:541–550.
   PubMed Web of Science ®Google Scholar
• Sridharan V, Gjini E, Liao X, et al. Immune profiling of adenoid cystic carcinoma: PD-L2 expression and associations with tumor-infiltrating lymphocytes. Cancer Immunol Res. 2016;4:679–687.
   PubMed Web of Science ®Google Scholar
• Brkic FF, Kadletz L, Jank B, et al. Pretreatment assessment of hematologic and inflammatory markers in adenoid cystic carcinoma: neutrophil/lymphocyte ratio is associated with multiple recurrences. Oral Surg Oral Med Oral Pathol Oral Radiol. 2019;127:408–416.
   PubMed Web of Science ®Google Scholar
• Xu B, Jungbluth AA, Frosina D, et al. The immune microenvironment and expression of PD-L1, PD-1, PRAME and MHC I in salivary duct carcinoma. Histopathology. 2019;75:672–682.
   PubMed Web of Science ®Google Scholar
• Arolt C, Meyer M, Ruesseler V, et al. Lymphocyte activation gene 3 (LAG3) protein expression on tumor-infiltrating lymphocytes in aggressive and TP53-mutated salivary gland carcinomas. Cancer Immunol Immunother [Internet]. 2020. DOI:10.1007/s00262-020-02551-6
   PubMed Web of Science ®Google Scholar
• Jeske SS, Weissinger SE, Veit JA, et al. Treatment-induced changes of lymphocyte subsets in patients with adenoid cystic carcinoma of the head and neck. Eur Arch Otorhinolaryngol. 2019;276:1465–1473.
   PubMed Web of Science ®Google Scholar
• Gupta A, Probst HC, Vuong V, et al. Radiotherapy promotes tumor-specific effector CD8+ T cells via dendritic cell activation. J Immunol. 2012;189:558–566.
   PubMed Web of Science ®Google Scholar
• Jiang W, Chan CK, Weissman IL, et al. Immune priming of the tumor microenvironment by radiation. Trends Cancer Res. 2016;2:638–645.
   Google Scholar
• Ruivo CF, Adem B, Silva M, et al. The biology of cancer exosomes: insights and new perspectives. Cancer Res. 2017;77:6480–6488.
   PubMed Web of Science ®Google Scholar
• Xu Z, Zheng X, Zheng J. Tumor-derived exosomes educate fibroblasts to promote salivary adenoid cystic carcinoma metastasis via NGF-NTRK1 pathway. Oncol Lett. 2019;18:4082–4091.
   PubMed Web of Science ®Google Scholar
• Yang -W-W, Yang L-Q, Zhao F, et al. Epiregulin promotes lung metastasis of salivary adenoid cystic carcinoma. Theranostics. 2017;7:3700–3714.
   PubMed Web of Science ®Google Scholar
• Hou J, Wang F, Liu X, et al. Tumor-derived exosomes enhance invasion and metastasis of salivary adenoid cystic carcinoma cells. J Oral Pathol Med. 2018;47:144–151.
   PubMed Web of Science ®Google Scholar
• Mittal SK, Roche PA. Suppression of antigen presentation by IL-10. Curr Opin Immunol. 2015;34:22–27.
   PubMed Web of Science ®Google Scholar
• Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci Transl Med. 2016;8:328rv4.
   PubMed Web of Science ®Google Scholar
• Chen G, Huang AC, Zhang W, et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PPD-L1 expression i response. Nature. 2018;560:382–386.
   PubMed Web of Science ®Google Scholar
• Poggio M, Hu T, Pai -C-C, et al. Suppression of exosomal PD-L1 induces systemic anti-tumor immunity and memory. Cell. 2019;177:414–427.e13.
   PubMed Web of Science ®Google Scholar
• Gong J, Chehrazi-Raffle A, Reddi S, et al. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer. 2018;6:8.
   PubMed Web of Science ®Google Scholar
• Cristescu R, Mogg R, Ayers M, et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science [Internet]. 2018;362:eaar3593.
   PubMed Web of Science ®Google Scholar
• Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer. 2019;19:133–150.
   PubMed Web of Science ®Google Scholar
• Kokkali S, Ntokou A, Drizou M, et al. Nivolumab in patients with rare head and neck carcinomas: a single center’s experience. Oral Oncol. 2020;101:104359.
   PubMed Web of Science ®Google Scholar
• Sato F, Akiba J, Kawahara A, et al. The expression of programed death ligand-1 could be related with unfavorable prognosis in salivary duct carcinoma. J Oral Pathol Med. 2018;47:683–690.
   PubMed Web of Science ®Google Scholar
• Chang H, Kim JS, Choi YJ, et al. Overexpression of PD-L2 is associated with shorter relapse-free survival in patients with malignant salivary gland tumors. Onco Targets Ther. 2017;10:2983–2992.
   PubMed Web of Science ®Google Scholar
• Harada K, Ferdous T, Ueyama Y. PD-L1 expression in malignant salivary gland tumors. BMC Cancer. 2018;18:156.
   PubMed Web of Science ®Google Scholar
• Mukaigawa T, Hayashi R, Hashimoto K, et al. Programmed death ligand-1 expression is associated with poor disease free survival in salivary gland carcinomas. J Surg Oncol. 2016;114:36–43.
   PubMed Web of Science ®Google Scholar
• Tapias LF, Shih A, Mino-Kenudson M, et al. Programmed death ligand 1 and CD8+ immune cell infiltrates in resected primary tracheal malignant neoplasms. Eur J Cardiothorac Surg. 2019;55:691–698.
   PubMed Web of Science ®Google Scholar
• Mosconi C, Arantes DAC, Gonçalves AS, et al. Immunohistochemical investigations on the expression of programmed cell death ligand 1, human leukocyte antigens G and E, and granzyme B in intraoral mucoepidermoid carcinoma. Arch Oral Biol. 2017;83:55–62.
   PubMed Web of Science ®Google Scholar
• Haderlein M, Scherl C, Semrau S, et al. Impact of postoperative radiotherapy and HER2/new overexpression in salivary duct carcinoma: a monocentric clinicopathologic analysis. Strahlenther Onkol. 2017;193:961–970.
   PubMed Web of Science ®Google Scholar
• Nakano T, Takizawa K, Uezato A, et al. Prognostic value of programed death ligand-1 and ligand-2 co-expression in salivary gland carcinomas. Oral Oncol. 2019;90:30–37.
   PubMed Web of Science ®Google Scholar
• Witte HM, Gebauer N, Lappöhn D, et al. Prognostic impact of PD-L1 expression in malignant salivary gland tumors as assessed by established scoring criteria: tumor proportion score (TPS), combined positivity score (CPS), and immune cell (IC) infiltrate. Cancers (Basel) [Internet]. 2020;12. DOI:10.3390/cancers12040873
   Web of Science ®Google Scholar
• Nance MA, Seethala RR, Wang Y, et al. Treatment and survival outcomes based on histologic grading in patients with head and neck mucoepidermoid carcinoma. Cancer. 2008;113:2082–2089.
   PubMed Web of Science ®Google Scholar
• Rozali EN, Hato SV, Robinson BW, et al. Programmed death ligand 2 in cancer-induced immune suppression. Clin Dev Immunol. 2012;2012:656340.
   PubMedGoogle Scholar
• Yearley JH, Gibson C, Yu N, et al. PD-L2 expression in human tumors: relevance to anti-PPD-L1 expression i therapy in cancer. Clin Cancer Res. 2017;23:3158–3167.
   PubMed Web of Science ®Google Scholar
• Zhao SG, Lehrer J, Chang SL, et al. The immune landscape of prostate cancer and nomination of PD-L2 as a potential therapeutic target. J Natl Cancer Inst. 2019;111:301–310.
   PubMedGoogle Scholar
• Tanegashima T, Togashi Y, Azuma K, et al. Immune suppression by PD-L2 against spontaneous and treatment-related antitumor immunity. Clin Cancer Res. 2019;25:4808–4819.
   PubMed Web of Science ®Google Scholar
• Cohen RB, Delord J-P, Doi T, et al. Pembrolizumab for the treatment of advanced salivary gland carcinoma: findings of the phase 1b KEYNOTE-028 study. Am J Clin Oncol [Internet]. 2018. DOI:10.1097/COC.0000000000000429
   Google Scholar
• Tchekmedyian V, Sherman EJ, Dunn L, et al. A phase II trial cohort of nivolumab plus ipilimumab in patients (Pts) with recurrent/metastatic adenoid cystic carcinoma (R/M ACC). J Clin Orthod. 2019;37:6084.
   Google Scholar
• Rodriguez CP, Wu QV, Voutsinas J, et al. A phase II trial of pembrolizumab and vorinostat in recurrent metastatic head and neck squamous cell carcinomas and salivary gland cancer. Clin Cancer Res. 2020;26:837–845.
   PubMed Web of Science ®Google Scholar
• Fayette J, Even C, Digue L, et al. NISCAHN: a phase II, multicenter nonrandomized trial aiming at evaluating nivolumab (N) in two cohorts of patients (pts) with recurrent/metastatic (R/M) salivary gland carcinoma of the head and neck (SGCHN), on behalf of the unicancer head & neck group. J Clin Orthod. 2019;37:6083.
   Google Scholar
• Kurzrock R, Bowles DW, Kang H, et al. Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study. Ann Oncol. 2020;31:412–421.
   PubMed Web of Science ®Google Scholar
• Ueta E, Osaki T, Yamamoto T, et al. Induction of differentiation in maxillary adenoid cystic carcinomas by adoptive immunotherapy in combination with chemoradiotherapy. Oral Oncol. 1998;34:105–111.
   PubMed Web of Science ®Google Scholar
• Pillai RN, Behera M, Owonikoko TK, et al. Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: a systematic analysis of the literature. Cancer. 2018;124:271–277.
   PubMed Web of Science ®Google Scholar
• Beppu S, Ito Y, Fujii K, et al. Expression of cancer/testis antigens in salivary gland carcinomas with reference to MAGE-A and NY-ESO-1 expression in adenoid cystic carcinoma. Histopathology. 2017;71:305–315.
   PubMed Web of Science ®Google Scholar
• Veit JA, Heine D, Thierauf J, et al. Expression and clinical significance of MAGE and NY-ESO-1 cancer-testis antigens in adenoid cystic carcinoma of the head and neck. Head Neck. 2016;38:1008–1016.
   PubMed Web of Science ®Google Scholar
• Scott AM, Wiseman G, Welt S, et al. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res. 2003;9:1639–1647.
   PubMed Web of Science ®Google Scholar
• Santos AM, Jung J, Aziz N, et al. Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. J Clin Invest. 2009;119:3613–3625.
   PubMed Web of Science ®Google Scholar
• Ngambenjawong C, Gustafson HH, Pun SH. Progress in tumor-associated macrophage (TAM)-targeted therapeutics. Adv Drug Deliv Rev. 2017;114:206–221.
   PubMed Web of Science ®Google Scholar
• Lim SY, Yuzhalin AE, Gordon-Weeks AN, et al. Targeting the CCL2-CCR2 signaling axis in cancer metastasis. Oncotarget. 2016;7:28697–28710.
   PubMedGoogle Scholar
• Tai Y-L, Chen K-C, Hsieh J-T, et al. Exosomes in cancer development and clinical applications. Cancer Sci. 2018;109:2364–2374.
   PubMed Web of Science ®Google Scholar
• Liu H, Chen L, Liu J, et al. Co-delivery of tumor-derived exosomes with alpha-galactosylceramide on dendritic cell-based immunotherapy for glioblastoma. Cancer Lett. 2017;411:182–190.
   PubMed Web of Science ®Google Scholar
• Morse MA, Garst J, Osada T, et al. A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med. 2005;3:9.
   PubMed Web of Science ®Google Scholar
• Besse B, Charrier M, Lapierre V, et al. Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC. Oncoimmunology. 2016;5:e1071008.
   PubMed Web of Science ®Google Scholar
• Fu M, Gu J, Jiang P, et al. Exosomes in gastric cancer: roles, mechanisms, and applications. Mol Cancer. 2019;18:41.
   PubMed Web of Science ®Google Scholar
• Leach DA, Need EF, Toivanen R, et al. Stromal androgen receptor regulates the composition of the microenvironment to influence prostate cancer outcome. Oncotarget. 2015;6:16135–16150.
   PubMedGoogle Scholar
• McAllister MJ, Underwood MA, Leung HY, et al. A review on the interactions between the tumor microenvironment and androgen receptor signaling in prostate cancer. Transl Res. 2019;206:91–106.
   PubMed Web of Science ®Google Scholar
• Kanda T, Takahashi K, Nakamura M, et al. Androgen receptor could be a potential therapeutic target in patients with advanced hepatocellular carcinoma. Cancers (Basel) [Internet]. 2017;9:43.
   PubMed Web of Science ®Google Scholar
• Shi Y, Fan X, Deng H, et al. Trastuzumab triggers phagocytic killing of high HER2 cancer cells in vitro and in vivo by interaction with Fcγ receptors on macrophages. J Immunol. 2015;194:4379–4386.
   PubMed Web of Science ®Google Scholar
• Park S, Jiang Z, Mortenson ED, et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell. 2010;18:160–170.
   PubMed Web of Science ®Google Scholar
• Xu M, Liu M, Du X, et al. Intratumoral delivery of IL-21 overcomes anti-her2/neu resistance through shifting tumor-associated macrophages from M2 to M1 phenotype. J Immunol. 2015;194:4997–5006.
   PubMed Web of Science ®Google Scholar
• Xu M, Du X, Liu M, et al. The tumor immunosuppressive microenvironment impairs the therapy of anti-HER2/neu antibody. Protein Cell. 2012;3:441–449.
   PubMed Web of Science ®Google Scholar
• Kato Y, Tabata K, Kimura T, et al. Lenvatinib plus anti-PPD-L1 expression i antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway. PLoS One. 2019;14:e0212513.
   PubMed Web of Science ®Google Scholar
• Wang Q, Guldner IH, Golomb SM, et al. Single-cell profiling guided combinatorial immunotherapy for fast-evolving CDK4/6 inhibitor-resistant HER2-positive breast cancer. Nat Commun. 2019;10:3817.
   PubMed Web of Science ®Google Scholar
• Hellmann MD, Nathanson T, Rizvi H, et al. Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer. Cancer Cell. 2018;33:843–852.e4.
   PubMed Web of Science ®Google Scholar
• Wang C, Hahn E, Slodkowska E, et al. Reproducibility of PD-L1 immunohistochemistry interpretation across various types of genitourinary and head/neck carcinomas, antibody clones, and tissue types. Hum Pathol. 2018;82:131–139.
   PubMed Web of Science ®Google Scholar
• Yamashita K, Iwatsuki M, Harada K, et al. Can PD-L1 expression evaluated by biopsy sample accurately reflect its expression in the whole tumour in gastric cancer? Br J Cancer. 2019;121:278–280.
   PubMed Web of Science ®Google Scholar
• Thorsson V, Gibbs DL, Brown SD, et al. The Immune Landscape of Cancer. Immunity. 2018;48:812–830.e14.
   PubMed Web of Science ®Google Scholar
• Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Science. 2015;348:74–80.
   PubMed Web of Science ®Google Scholar